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A commentary on
On the role of dendritic cells versus other
cells in inducing protective CD8+ T cell
responses
by Zinkernagel RM (2014) Front Immunol
5:30. doi:10.3389/ fimmu.2014.00030
(1) In the face of MHC-class I-restricted
direct presentation from a live, repli-
cating viral infection – after the
groundbreaking discovery of the MHC
restriction of T cell responses by Rolph
Zinkernagel and Peter Doherty (1) –
cross-presentation is indeed a weaker
phenomenon (2, 3). Antigen present-
ing cells can cross-present exogenous
antigens from viruses which cannot
infect them, allowing anti-viral MHC-
class I-restricted, CD8+, cytotoxic T
cell priming (4). Nevertheless, when
direct presentation is available, cross-
presentation is dispensable for eliciting
a maximal anti-vaccinia virus CD8+ T
cell response (5).
(2) Demonstration of cross-priming often
uses sensitive detection methods
requiring the infusion of high numbers
of T cell receptor-transgenic mouse T
cells (3). However, in many studies,
natural CD8 T cell responses to epi-
topic peptides were induced in mice by
cross-priming (6–11).
(3) Dendritic cells (DC) and/or
macrophages are indeed key trans-
porters of antigens to secondary
lymphoid organs (12–16).
(4) Via class I, DC present phago-
cytosed antigens from intracellular
viruses, bacteria, and other microor-
ganisms, but also from non-replicating
microorganisms [HIV inactivated by
antiprotease, replication level proven
unable to induce direct presentation
(17)], apoptotic cells or tumor cell-
derived fragments (9), or even live
cells [DC purified after culture with
live tumor cells, then injected, and
the wash-out from these cells, contain-
ing potentially contaminating antigen
from these tumor cells, is not able to
present directly (18)]. This can lead to
protective vaccination against tumors
(18–20).
(5) Location in secondary lymphoid
organs or tertiary lymphatic tissues
may indeed be the key to CD8 T cell
priming. Any cell type may be able
to prime CD8 T lymphocytes when
located in lymphatic tissues and cor-
rectly activated (21–23). This in turn
requires appropriate draining of these
cells into lymphatic tissues to pro-
vide antigen amounts high enough
for cross-presentation, in the presence
of the appropriate costimulation and
cytokines to induce either immune
responses or active tolerance. This
conjunction of circumstances may be
obtained less rarely with DC than with
other cell types, thanks to their high
expression of class I molecules, cos-
timulation molecules and cytokines,
and their high propensity to trans-
port antigens to lymphatic tissues. This
can yield the direct presentation of
endogenous epitopes. Why would not
it also yield the cross-presentation of
exogenous antigens?
(6) During HIV infection, like in LCMV
infection, chronic type I IFN pro-
duction and immune hyperactiva-
tion induce immune suppression. Live
replicating recombinant vaccine vec-
tors that induce efficient direct presen-
tation are not acceptable for immune
therapy in populations with poten-
tial immune deficiency, for safety
reasons. In addition, these vectors
require the use of sequences, which
will not mutate like the actual
patient’s viral sequences. Why not try
and exploit this opportunity to stir
the balance of HIV-specific immune
responses toward immunity instead of
tolerance?
(7) Tumors also favor suppressive mech-
anisms (negative costimulation mol-
ecules like CTLA-4 and PD-1, sup-
pressive cytokines like IL-10, myeloid-
derived suppressor cells). After tumor
ablation, it may be hoped in the
future to restore immune surveillance
by anti-suppressive agents and thera-
peutic vaccination. Recombinant vac-
cines expressing tumor antigens for
direct presentation require the use
of sequences, which will not mutate
like the actual patient’s tumor anti-
gen sequences. Antigens from dead
tumor cells can be crosspresented,
even though with a low efficiency,
by DC, yielding protection against
tumors in vivo (in experimental set-
tings that are still artificial but protec-
tive) (9); this can be obtained more
efficiently using live tumor cells (18).
Why not try and exploit this opportu-
nity to stir the balance of antitumoral
immune responses toward immunity
instead of tolerance?
(8) When major direct antigen presen-
tation is not as blatant as during
replicative viral infections, or is not
exploitable for safety reasons, the alter-
native cross-presentation pathway may
be exploitable for therapy.
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